All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2021-06-25T07:26:49.000Z

Satellite Symposium | How to treat early relapse in a patient with FL

Bookmark this article

The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a panel of international experts come together to discuss the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia. Professor Loretta J. Nastoupil, MD Anderson Cancer Center, Houston, US, discusses how to treat early relapse in a patient with follicular lymphoma (FL).

Lymphoma Hub Satellite Symposium: Watch here!

Welcome to the Lymphoma Hub Satellite Symposium.

Please take a moment to complete the survey and answer the following questions to help us gauge your current understanding of the sequencing of therapy for patients with early relapsing FL.

Nastoupil begins by outlining a clinical case and the benefits of utilizing PET scans to exclude transformation as the driver of poor outcomes. The presentation then reviews therapeutic options and the data that inform treatment selection, including data from the GADOLIN, AUGMENT, GALEN, and SWOG trials. Finally, Nastoupil describes how she would approach this case, utilizing available clinical trials that employ novel agents, such as tazemetostat and tafasitamab, and she offers insight for those that practice in a different setting.

Satellite Symposium | How to treat early relapse in a patient with FL

If you would like to download the slides from Loretta Nastoupil's presentation, click below

Download here

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
55 votes - 65 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox